Literature DB >> 3865561

Malignant hyperthermia.

L Taiclet.   

Abstract

Despite numerous reviews and clinical reports, much remains to be learned about the cause, treatment, and prevention of malignant hyperthermia.Among the most worrisome concerns of the clinician administering anesthesia is the malignant hyperthermia crisis. When it arises, it is always frightening-and sometimes fatal. Usually occurring very suddenly and without warning, malignant hyperthermia is considered to be a hypercatabolic crisis; the condition is known to affect humans and certain breeds of pigs. The exact triggering mechanisms of malignant hyperthermia (MH) in humans are not known, but a crisis can be initiated by volatile general anesthetics, neuromuscular blocking agents, and amide local anesthetics. Although a history of an MH crisis is a diagnostic aid, previous uneventful exposure to anesthesia does not guarantee the safety of the patient in subsequent anesthetic procedures.(1) For these reasons, it is important for the anesthesiologist to be aware of the initial signs of MH and to be prepared to provide immediate treatment to reverse such a crisis.

Entities:  

Mesh:

Year:  1985        PMID: 3865561      PMCID: PMC2148536     

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  20 in total

1.  Malignant hyperthermia--the acute crisis.

Authors:  D J Steward
Journal:  Int Anesthesiol Clin       Date:  1979

2.  Sevoflurane triggers malignant hyperthermia in swine.

Authors:  M Shulman; B Braverman; A D Ivankovich; G Gronert
Journal:  Anesthesiology       Date:  1981-03       Impact factor: 7.892

3.  Malignant hyperthermia: platelet bioassay.

Authors:  C C Solomons; N Masson
Journal:  Anesthesiology       Date:  1984-03       Impact factor: 7.892

4.  Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia.

Authors:  G Ruhland; A J Hinkle
Journal:  Anesthesiology       Date:  1984-02       Impact factor: 7.892

5.  Potential value of expiratory carbon dioxide measurement in patients considered to be susceptible to malignant hyperthermia.

Authors:  L Triner; J Sherman
Journal:  Anesthesiology       Date:  1981-10       Impact factor: 7.892

6.  Evidence for in vivo biotransformation of nitrous oxide.

Authors:  C G Lou; D W Wingard
Journal:  Anesthesiology       Date:  1981-06       Impact factor: 7.892

7.  Platelet aggregation in patients susceptible to malignant hyperthermia.

Authors:  H Rosenberg; C A Fisher; S B Reed; V P Addonizio
Journal:  Anesthesiology       Date:  1981-12       Impact factor: 7.892

8.  Malignant hyperthermia following preoperative oral administration of dantrolene.

Authors:  D C Fitzgibbons
Journal:  Anesthesiology       Date:  1981-01       Impact factor: 7.892

9.  Metabolic rate and blood hormone and metabolite levels of individuals susceptible to malignant hyperpyrexia at rest and in response to food and mild exercise.

Authors:  I T Campbell; F R Ellis; R T Evans
Journal:  Anesthesiology       Date:  1981-07       Impact factor: 7.892

Review 10.  Etiology and pathophysiology of malignant hyperthermia.

Authors:  M A Denborough
Journal:  Int Anesthesiol Clin       Date:  1979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.